Eight Senators Want a Tougher 7-OH Ban. Nobody Has a Plan for the People Already Hooked.
The DEA's narrowed 7-OH order still isn't final, Congress is pushing to widen it, and the people buying it at smoke shops are the last ones anyone has asked.
A 41-year-old man NPR identified only as Brian described the moment he understood what the little gas-station tablets had done to him in three words: “It was game over.” Another man, Tyler, 38, gave the diagnosis most clinicians would: “It’s just too addictive and too accessible.” Neither of them got there by chasing a high from a dealer. They got there from a shelf.
A ban that takes 7-OH off the shelf without putting withdrawal care on the calendar doesn’t end anyone’s dependence. It just moves it somewhere darker.
That is the gap in this week’s fight. On November 17, Pain News Network reported that eight Republican senators, led by Chuck Grassley, wrote to the DEA and FDA demanding the agency return to its original, broader scheduling of 7-hydroxymitragynine and the related compound mitragynine pseudoindoxyl. Their letter is blunt — “Kratom is an opioid” — and they want an answer by November 30. The DEA’s revised notice from October 14 would put only products above 1 milligram per serving into Schedule I. As of this week, no final order has been published.
The senators are not wrong about the pharmacology. 7-OH is a concentrated version of a compound that occurs in tiny amounts in the kratom leaf, and it hits the same brain receptors heroin and fentanyl do. Your brain does not care whether the bottle had a barcode. The dependence that follows is opioid dependence, and the withdrawal — the restless legs, the sweats, the 3 a.m. certainty that one more will make it stop — is opioid withdrawal. That is why the people who use it describe it the way Brian does.
The bodies are starting to be counted. New Mexico’s health department linked 29 deaths from 2019 to 2024 to kratom — though fentanyl was involved in 15 and only four involved kratom alone, and standard toxicology panels don’t test for it, so the real number is unknown. In northern Michigan, where there is no age limit on purchases, coroners tied at least two summer deaths to kratom, and a Traverse City treatment provider said it sees “at least 100 people per year” for kratom or 7-OH addiction.
We wrote earlier this month about Arizona’s 7-OH ban arriving before the treatment beds. Washington is about to repeat that mistake at national scale. If you are taking 7-OH every day, you are not a criminal-in-waiting — you have opioid dependence, and opioid dependence has real treatment. Tell a prescriber what you take, by name.
For clinics: add “kratom” and “7-OH” by name to every intake form this week, because nobody volunteers a product they bought legally and a urine screen won’t find it for you.
The shelf is going to empty. The people who bought from it are going to stay exactly where they are.
More in our novel and emerging substances hub.
Sources Cited
- 01.B
- 02.B
- 03.A
- 04.BHealth department study links kratom to 29 overdose deaths in New MexicoAlbuquerque Journal
- 05.BKratom overdose cited in at least two deathsTraverse City Record-Eagle / Detroit News
Filed Under
psychologypolicyharm-reductionKratomDEADrug SchedulingFederalThe Treatment GapOverdose
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
The Senate Just Told SAMHSA to Explain Its Own Harm Reduction Rules. Grantees Have Been Asking All Year.
The Senate's FY27 Labor-HHS bill funds SAMHSA at about $7.46 billion, rejects merging NIDA and NIAAA, and orders SAMHSA to give grantees 'timely and clarifying guidance' on harm reduction. The deadline that matters is December 11.
Policy & FundingThe DEA Watched Fentanyl Walk Into Albuquerque. Now the City Is Sending the Bill.
Albuquerque says DEA agents let millions of fentanyl pills reach its streets to build bigger cases, and it wants $153 million. Here is what 'walking' cost, who paid, and why Arizona has seen this movie before.
Policy & FundingWashington Is Finally Funding Ibogaine Research. It's Borrowing the Safety Record From a Clinic That Sells the Trip.
ARPA-H will spend up to $4.9M to prepare ibogaine trials for PTSD, using a commercial Mexico clinic's data. Why that matters for people hoping ibogaine can treat opioid addiction.